ABSTRACT: 

(IBS) or Irritable bowel syndrome is a complicated health condition with different causative factors, including inflammation and infection, that have recently acquired as significant triggers of IBS. Inflammatory response might serve as a critical pathway in the progression of IBS, beside inequality in cytokines within the plasma and/or intestinal mucosal lining. Many biomarkers have been associated to possible mechanisms underlying IBS and are used to make differentiation between IBS and non-IBS subjects. Incorporation of these biomarkers into routine clinical work is important for fast and accurate diagnosis and effective treatment. Because IBS patients often experience ambiguous and overlapping symptoms, the creation of precise biomarkers for IBS could significantly enhance both diagnosis and patient care. This review examines the cytokines used in the diagnosis and treatment of IBS, Classifying these cytokines as either pro-inflammatory or anti-inflammatory and understanding their involvement in the development of irritable bowel syndrome.

REFERENCES :

1) Amani, R., Abbasnezhad, A., Hajiani, E., Cheraghian, B., Abdoli, Z., & Choghakhori, R. (2018). Vitamin D3 Induced Decrease in IL-17 and Malondialdehyde, and Increase in IL-10 and Total Antioxidant Capacity Levels in Patients with Irritable Bowel Syndrome. Iranian journal of immunology : IJI, 15(3), 186–196. https://doi.org/10.22034/IJI.2018.39388
2) Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome: a systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels. Cytokine. 2017;99:132–8.
3) Bashier Eltayeb, L., Shams, D., Babikr, N., Madani, M., Abdelghani, S., & Ali Waggiallah, H. (2020). Serum Levels of Interferon Gamma INF-γ and Interleukin 10 Il-10: an Immunological Aspect among Irritable Bowel Syndrome Patients. Pakistan journal of biological sciences : PJBS, 23(7), 898–903. https://doi.org/10.3923/pjbs.2020.898.903
4) Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, de Giorgio R, et al. (2009) Mucosal immune activation in irritable bowel syndrome: Gender-dependence and association with digestive symptoms. Am J Gastroenterol.;104(2):392–400.
5) Dothel, G., Barbaro, M. R., Di Vito, A., Ravegnini, G., Gorini, F., Monesmith, S., Coschina, E., Benuzzi, E., Fuschi, D., Palombo, M., Bonomini, F., Morroni, F., Hrelia, P., Barbara, G., & Angelini, S. (2023). New insights into irritable bowel syndrome pathophysiological mechanisms: contribution of epigenetics. Journal of gastroenterology, 58(7), 605–621. https://doi.org/10.1007/s00535-023-01997-6
6) Galani, V., Kastamoulas, M., Varouktsi, A., Lampri, E., Mitselou, A., & Arvanitis, D. L. (2017). IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review. Clinical and experimental medicine, 17(3), 281–289.
https://doi.org/10.1007/s10238-016-0432-3
7) Hadi, W. S., Salman, R. S., Al-Fahham, A. A., Faryad Khan, M. U., Kadir, S., Laft, M. H., Saeed, B. Q., Kadhum, W. R., Jalil, A. T., & Kadhim, M. M. (2022). Evaluation of IL-17 and IL-35 in patients with giardiasis in Thi-Qar province, Iraq. Journal of medicine and life, 15(9), 1096–1099. https://doi.org/10.25122/jml-2021-0328
8) Kindt, S., Van Oudenhove, L., Broekaert, D., Kasran, A., Ceuppens, J. L., Bossuyt, X., Fischler, B., & Tack, J. (2009). Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterology and motility, 21(4), 389–398. https://doi.org/10.1111/j.1365-2982.2008.01220.x.
9) Kumar S, Shukla R, Ranjan P, Kumar A. (2017) Interleukin-10: a compelling therapeutic target in patients with irritable bowel syndrome. Clin Ther.;39(3):632–43.
10) Kumar, S., Singh, P. & Kumar, A. (2022) Targeted therapy of irritable bowel syndrome with anti-inflammatory cytokines. Clin J Gastroenterol 15, 1–10. https://doi.org/10.1007/s12328-021-01555-8
11) Lazaridis N, Germanidis G. (2018) Current insights into the innate immune system dysfunction in irritable bowel syndrome. Anna Gastroenterol.;31(2):171.
12) Martínez C, González-Castro A, Vicario M, Santos J. (2012) Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome. Gut Liver.;6(3):305.
13) Mitselou, A., Grammeniatis, V., Varouktsi, A., Papadatos, S. S., Katsanos, K., & Galani, V. (2020). Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease. Intestinal research, 18(1), 115–120. https://doi.org/10.5217/ir.2019.00125
14) Nakov, R., Snegarova, V., Dimitrova-Yurukova, D., & Velikova, T. (2022). Biomarkers in Irritable Bowel Syndrome: Biological Rationale and Diagnostic Value. Digestive diseases (Basel, Switzerland), 40(1), 23–32.
https://doi.org/10.1159/000516027
15) Patel SR, Singh A, Misra V, Misra SP, Dwivedi M, Trivedi P. (2017) Levels of interleukins 2, 6, 8, and 10 in patients with irritable bowel syndrome. Indian J Pathol Microbiol.;60(3):385-389. doi:10.4103/IJPM.IJPM_544_16
16) Piche, T., Barbara, G., Aubert, P., Bruley des Varannes, S., Dainese, R., Nano, J. L., Cremon, C., Stanghellini, V., De Giorgio, R., Galmiche, J. P., & Neunlist, M. (2009). Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut, 58(2), 196–201.
https://doi.org/10.1136/gut.2007.140806.
17) Surdea-Blaga T, Bǎban A, Dumitrascu DL. (2012) Psychosocial determinants of irritable bowel syndrome. World J Gastroenterol.;18(7):616.
18) Vara EJ, Brokstad KA, Hausken T, Lied GA. (2018) Altered levels of cytokines in patients with irritable bowel syndrome are not correlated with fatigue. Internat J General Med.;11:285.